PR Newswire
MISSISSAUGA, ON, Nov. 2, 2020
MISSISSAUGA, ON, Nov. 2, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI) (OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2020 financial results before markets open on Monday, November 16, 2020 .
The Company will subsequently hold a conference call the same day, Monday, November 16, 2020 at 8:30 a.m. ET , hosted by Jesse Ledger , Nuvo's President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.
CONFERENCE CALL DETAILS
DATE: | Monday, November 16, 2020 |
| |
TIME: | 8:30 a.m. ET |
| |
DIAL-IN NUMBER: | 416 764 8688 or 1 888 390 0546 |
| |
TAPED REPLAY: | 416 764 8677 or 1 888 390 0541 / REPLAY PASSCODE: 499774# |
The audio webcast can be accessed at:
https://produceredition.webcasts.com/starthere.jsp?ei=1387608&tp_key=8417e4c6b2
An archived replay of the webcast will be available by clicking the link above.
About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Nuvo's head office is located in Mississauga, Ontario, Canada , the international operations are located in Dublin, Ireland and the U.S. Food and Drug Administration (FDA), Health Canada and E.U. approved manufacturing facility is located in Varennes , Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the FDA. For additional information, please visit www.nuvopharmaceuticals.com .
SOURCE Nuvo Pharmaceuticals Inc.